18:29 , Aug 10, 2018 |  BC Week In Review  |  Clinical News

Strongbridge's Cushing syndrome candidate meets in Phase III

Strongbridge Biopharma plc (NASDAQ:SBBP) said Recorlev levoketoconazole met the primary and secondary endpoints in the Phase III SONICS trial to treat endogenous Cushing syndrome. On the 94-patient trial's primary endpoint, 30% of patients achieved normalization of...
16:54 , Oct 6, 2017 |  BC Week In Review  |  Financial News

NewLink, Strongbridge price follow-ons

NewLink Genetics Corp. (NASDAQ:NLNK) and Strongbridge Biopharma plc (NASDAQ:SBBP) each priced follow-ons, raising more than $75 million. On Oct. 3, NewLink raised $51.3 million through the sale of 5 million shares at $10.25 in a bumped-up...
21:14 , Oct 4, 2017 |  BC Extra  |  Financial News

NewLink, Strongbridge price follow-ons

NewLink Genetics Corp. (NASDAQ:NLNK) and Strongbridge Biopharma plc (NASDAQ:SBBP) each priced follow-ons, raising more than $75 million. NewLink raised $51.3 million through the sale of 5 million shares at $10.25 in a bumped-up follow-on underwritten by...
01:30 , Oct 17, 2015 |  BC Extra  |  Financial News

Strongbridge raises $25M in U.S. listing

Strongbridge Biopharma plc (NASDAQ:SBBP) gained $0.05 to $10.05 in its first day of trading on NASDAQ on Friday after it raised $25 million through the sale of 2.5 million shares at $10 in a deal...
02:37 , Oct 31, 2014 |  BC Extra  |  Financial News

Cortendo pulls Oslo IPO to mull U.S. listing, raises $11.3M

Cortendo AB (Gothenburg, Sweden) said it will raise SEK 81.5 million ($11.3 million) in a private placement. The company will also drop plans to list on the Oslo Axess exchange and consider a U.S. listing...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Clinical News

NormoCort: Phase III started

Cortendo began the open-label, international Phase III SONICS trial to evaluate ascending doses of twice-daily oral NormoCort in about 90 patients with Cushing’s syndrome. The trial comprises a dose-titration phase of 2-16 weeks, a maintenance...